{"nct_id":"NCT04165083","title":"KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-09","start_date":"2020-12-22","start_date_type":"ACTUAL","primary_completion_date":"2025-10-31","primary_completion_date_type":"ESTIMATED","completion_date":"2025-10-31","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["MRK"]}